| Literature DB >> 35371468 |
Simoni Khashu1, Nitya Wanchoo2, Kayla D Finuf3, Sebastian Lapman4, Prakash Gudsoorkar5, Kenar D Jhaveri6.
Abstract
Graphical Abstract.Entities:
Keywords: AKI; CKD; cancer; chronic renal failure; nephrotoxicity
Year: 2021 PMID: 35371468 PMCID: PMC8967669 DOI: 10.1093/ckj/sfab281
Source DB: PubMed Journal: Clin Kidney J ISSN: 2048-8505
FIGURE 1:(A–D) How did the WhatsApp® chat help your quest for education, research and collaboration in Onconephrology (Q8–10). Survey results of what most participants used to answer their Onconephrology questions (Q17).
FIGURE 2:Keywords from the WhatsApp® Onconephrology chat (number of times mentioned). Biopsy (219); thrombotic microangiopathy, TMA (133); acute kidney injury, AKI (132); cancer (81); proteinuria (74); nephrotic syndrome (37); membranous nephropathy (36); lymphoma (32); bone marrow transplant (31); acute interstitial nephritis, AIN (28); transplant (28); acute tubular necrosis, ATN (26); paraneoplastic (18); capillary leak (15). The most common medications mentioned (number of times) were as follows: immune checkpoint inhibitors, ICI (88); anti-vascular endothelial growth factors, VEGFI (44); tyrosine kinase inhibitors, TKI (38); cisplatin (25); chemo (22). Other keywords mentioned were cytokines (29) and complement (28).
Summary of the various themes noted in the WhatsApp® Onconephrology chat
| Theme | Example | Additional information |
|---|---|---|
| Collaboration | P1: Hello, has anyone seen a case of AKI with Palbociclib? Is this real or pseudo-AKI? | Group members collaborated to form a case series to eventually describe a new lesion/lesion with a novel group of cancer agents. |
| P2: I have seen several cases of pseudo-AKI with this class of agents—CDK4/6 inhibitors. Did you measure cystatin-based GFR? | ||
| P1: Yes, this is true AKI. | ||
| P4: I have a case of biopsy-proven ATI with a similar CDK 4/6 inhibitor. | ||
| P5: Perhaps, we should collect all cases that we are seeing of pseudo-AKI and biopsy-proven ATI with this agent. | ||
| P1: Let us do that; that would be helpful to the community. | ||
| Patient care/case management | P1: Hello all. Wanted to get the group's thoughts on using (dose-adjusted) carboplatin in patients with high-risk bladder cancer but eGFR ≈ 25 (< 30). | Group members posted clinical questions to garner feedback from other members to address a clinical concern. Questions could be based on a singular patient (see example) or on cohorts of patients such as geriatric patients. Messages typically reflected situations in which the original posting member would ask a specific question and other group members would weigh in on the issue at hand and provide recommendations. |
| P2: Certainly, far less nephrotoxicity than cisplatin, but it has been reported to be associated with AKI. I would support its use if it is the best treatment option. | ||
| P3: I will also support its use with the appropriate dose adjustment. I think it must be adjusted according to CrCl. | ||
| P4: Carbo is not completely benign, I have certainly seen nephrotoxicity with it, and very severe hypomagnesemia as well. The AUC-based dosing can be reduced in case of problems. I think the nephrotoxicity is ∼7% as compared to cisplatin, which is ∼25% | ||
| P1: Thanks guys. This patient has had a nephrectomy but still has an unresectable tumor in the bladder and has a high-grade tumor, so high risk of recurrence. I was thinking of asking the oncologist to target AUC around 4 instead of 5 or 6 as they usually do. | ||
| P3: Immunotherapy is another option. | ||
| Knowledge sharing | P1: | Group members used the platform to share research articles or other educational material. This included direct links to recently published articles, uploaded documents, or files of published or unpublished manuscripts and data, and uploaded images depicting pathology scenarios. Shared files or links were likely to spur additional dialogue surrounding the topic. Additionally, shared topics could provide examples of topics that were not widely recognized by the larger community. |
| P1: A question by one of my colleagues after reading the blog: Does plasma exchange have any role in removal of MTX, given that it is protein bound? As glucarpidase is not available here! | ||
| P2: That is a good question. I do not know why we did not notice plasma exchange as a treatment. Anyway, I think it seems likely more effective than hemodialysis HFlux. |
P1, P2, P3, P4, P5: Deidentified participants 1, 2, 3, 4, 5, involved in the Onconephrology WhatsApp® chat. AKI, acute kidney injury; (e)GFR, (estimated) glomerular filtration rate; ATI, acute tubular injury; CDK, cyclin-dependent kinase; CrCl, creatinine clearance; AUC, area under the curve; MTX, methotrexate.